We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Protein-Lipid Link Common to Chronic Lung Disorders

By LabMedica International staff writers
Posted on 10 Jan 2011
Chronic lung diseases share a link between the ceramide class of lipids and the protein CFTR (cystic fibrosis transmembrane conductance regulator), which is present in a mutated and inactive form in cystic fibrosis.

Ceramides, which are composed of sphingosine and a fatty acid, are found in high concentrations within the cell membrane. More...
They comprise one of the component lipids that constitute sphingomyelin, one of the major lipids in the lipid bilayer. In addition to a purely structural role, ceramide can act as a signaling molecule. The best-known functions of ceramides as cellular signals include regulating differentiation, proliferation, and apoptosis. Ceramide has also been shown to form organized large channels traversing the mitochondrial outer membrane. This leads to the migration of proteins from the intermembrane space.

How ceramide acts as a signaling molecule is not clear. One hypothesis is that ceramide generated in the plasma membrane stabilizes smaller lipid platforms known as lipid rafts, allowing them to serve as platforms for signaling molecules. Moreover, as rafts can cross the entire lipid bilayer, they can serve as the link between signals outside of the cell to signals to be generated within the cell.

In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) worked with a mouse model that included a line of mice that had been genetically engineered to lack the gene for CFTR. Findings from the mouse model were confirmed by analysis of tissues taken from humans with and without chronic lung disorders.

The investigators reported in the December 6, 2010, online edition of the Journal of Immunology that CFTR expression inversely correlated with the severity of emphysema and ceramide accumulation in chronic obstructive pulmonary disease subjects compared with control subjects. The lower the CFTR expression, the higher the level of ceramide and the more severe was the lung condition. Comparing normal and CFTR-deficient mice, they found that that membrane-CFTR was required for controlling lipid-raft ceramide levels.

Since low CFTR caused an increase in the level of ceramide, the investigators tested two drugs that inhibit ceramide synthesis on mice with lung damage caused by a bacterial infection. One of the inhibitors, FB1, successfully decreased ceramide buildup in mice with normal CFTR but did not prevent ceramide accumulation in mice lacking CFTR. The other drug, AMT, blocked ceramide increase in the mice lacking CFTR, while failing to do so in those with decreased CFTR.

"Our findings suggest that CFTR is a multitasker protein that is not only involved in chloride transport but also in regulating cell death and inflammation by keeping in check the rampant and dangerous accumulation of ceramide," said senior author Dr. Neeraj Vij, assistant professor of pediatrics at Johns Hopkins University. "We anticipate that membrane CFTR and ceramide may turn out to be useful predictors of susceptibility to lung damage from smoking and infections and may be tailored for drug therapy to alter disease course."

Related Links:
Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.